 |
市场调查报告书
商品编码
1535724
抗球虫药物市场 - 按药物类别（合成化合物、聚醚抗生素或离子载体）、药物作用（抑制球虫、杀球虫）、动物类型（伴侣、牲畜）、配销通路、全球预测（2024 - 2032 ）Anticoccidial Drugs Market - By Drug Class (Synthetic Compounds, Polyether Antibiotics or Ionophores), Drug Action (Coccidiostatic, Coccidiocidal), Animal Type (Companion, Livestock), Distribution Channel, Global Forecast (2024 - 2032) |
||||||
在动物健康意识不断提高以及转向天然和替代解决方案的推动下，全球抗球虫药物市场在 2024 年至 2032 年间将实现 4.1% 的复合年增长率。随着消费者和生产者越来越重视动物福利，对有效的非抗生素治疗的需求不断增长。这一趋势促进了天然抗球虫药物的开发和采用，从而提供更安全、更永续的疾病管理。专注于增强动物健康，同时最大限度地减少抗生素的使用，以满足不断变化的市场需求，从而促进行业的显着增长。
例如，2022 年 4 月，Amlan International 为牲畜和家禽推出了两种新的天然抗生素替代品：Phylox(R) Feed 和 NeutraPath(R)。这些产品无需使用抗生素即可增强肠道健康并提高生产经济效益。这些新产品可增强肠道健康和生产效益，可能透过推广天然解决方案并可能扩大畜禽管理选择来影响市场动态。
抗球虫药物产业根据药物类别、药物作用、动物类型、配销通路和地区而分散。
到 2032 年，杀球虫领域将大幅成长，因为它能有效杀死球虫寄生虫并防止球虫病的传播。这些药物在管理和控制牲畜、家禽和其他动物的感染方面发挥着至关重要的作用，有助于维持生产力并减少经济损失。杀球虫药物在治疗现有感染和预防新疫情方面的高效性推动了其在该行业中的主导地位，因为它们对于确保动物健康和优化农业产量至关重要。
由于畜牧业对有效疾病管理的迫切需求，到 2032 年，畜牧业将取得显着进展。抗球虫药物对于预防和治疗球虫病至关重要，球虫病是一种影响牲畜并可能导致重大经济损失的寄生虫感染。随着对肉类和乳製品的需求增加，农民和生产者越来越依赖这些药物来维持动物健康和生产力。对改善牲畜福利和减少疾病爆发的关注支撑了该领域的主导地位。
由于严格的监管标准、先进的兽医实践和较高的畜牧生产水平，欧洲抗球虫药物市场到 2032 年将保持适度的复合年增长率。该地区致力于维持严格的动物健康方案和预防疾病爆发，这推动了对有效抗球虫解决方案的需求。此外，欧洲致力于整合创新疗法并确保高品质的动物护理，这也为其带来了巨大的市场份额。监管支持、行业标准和技术进步的结合使欧洲成为全球抗球虫药物行业的显着贡献者。
目录
第 1 章：方法与范围
第 2 章：执行摘要
第 3 章：产业洞察
- 产业生态系统分析
- 产业影响力
- 成长动力
- 球虫病发生率增加
- 不断增长的牲畜数量
- 对动物性蛋白质的需求不断增长
- 产业陷阱与挑战
- 药物研发成本高
- 严格的监管要求
- 成长动力
- 成长潜力分析
- 监管环境
- 技术景观
- 波特的分析
- PESTEL分析
第 4 章：竞争格局
- 介绍
- 公司市占率分析
- 公司矩阵分析
- 主要市场参与者的竞争分析
- 竞争定位矩阵
- 战略仪表板
第 5 章：市场估计与预测：按药物类别，2021 - 2032 年
- 主要趋势
- 合成化合物
- 聚醚抗生素或离子载体
第 6 章：市场估计与预测：按药物行动，2021 - 2032 年
- 主要趋势
- 抑制球虫
- 杀球虫剂
第 7 章：市场估计与预测：按动物类型，2021 - 2032
- 主要趋势
- 伴侣动物
- 狗
- 猫
- 其他伴侣动物
- 畜牧动物
- 牛
- 家禽
- 其他家畜动物
第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年
- 主要趋势
- 兽医医院和药房
- 零售药局
- 其他分销管道
第 9 章：市场估计与预测：按地区划分，2021 - 2032 年
- 主要趋势
- 北美洲
- 我们
- 加拿大
- 欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
- 亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
- 拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
- 中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区
第 10 章：公司简介
- Bayer AG
- Boehringer Ingelheim International GmbH
- Ceva
- Cronus Pharma LLC
- Elanco Animal Health Incorporated
- Huvepharma EOOD
- Impextraco NV
- Merck & Co., Inc.
- Phibro Animal Health Corporation
- Vetoquinol SA
- Virbac SA
- Zoetis Inc.
Global Anticoccidial Drugs Market will achieve a 4.1% CAGR between 2024 and 2032, driven by rising awareness of animal health and a shift towards natural and alternative solutions. As consumers and producers increasingly prioritize animal welfare, there is a growing demand for effective, non-antibiotic treatments. This trend promotes the development and adoption of natural anticoccidial options that offer safer and more sustainable disease management. The focus on enhancing animal health while minimizing antibiotic use aligns with evolving market needs, contributing to significant industry growth.
For instance, in April 2022, Amlan International introduced two new natural alternatives to antibiotics for livestock and poultry: Phylox(R) Feed and NeutraPath(R). These products enhance intestinal health and improve production economics without using antibiotics. These new products offer enhanced intestinal health and production benefits, which may influence market dynamics by promoting natural solutions and potentially expanding options for livestock and poultry management.
The anticoccidial drugs industry is fragmented based on drug class, drug action, animal type, distribution channel, and region.
The coccidiocidal segment will see a considerable surge by 2032, attributed to its effectiveness in killing coccidia parasites and preventing the spread of coccidiosis. These drugs play a crucial role in managing and controlling infections in livestock, poultry, and other animals, which helps to maintain productivity and reduce economic losses. The high efficacy of coccidiocidal drugs in treating existing infections and preventing new outbreaks drives their dominance in the industry, as they are essential for ensuring animal health and optimizing agricultural output.
The livestock animals segment will garner remarkable gains by 2032 due to the critical need for effective disease management in animal agriculture. Anticoccidial drugs are essential for preventing and treating coccidiosis, a parasitic infection that affects livestock and can lead to major economic losses. As the demand for meat and dairy products rises, farmers and producers increasingly rely on these drugs to maintain animal health and productivity. The focus on improving livestock welfare and reducing disease outbreaks supports the segment's dominance.
Europe anticoccidial drugs market will secure a moderate CAGR through 2032, owing to its stringent regulatory standards, advanced veterinary practices, and high livestock production levels. The region's focus on maintaining rigorous animal health protocols and preventing disease outbreaks drives demand for effective anticoccidial solutions. Besides, Europe's commitment to integrating innovative treatments and ensuring high-quality animal care contributes to its substantial market share. This combination of regulatory support, industry standards, and technological progress makes Europe a notable contributor to the global anticoccidial drugs industry.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing incidence of coccidiosis
- 3.2.1.2 Growing livestock population
- 3.2.1.3 Rising demand for animal protein
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High cost of drug development
- 3.2.2.2 Stringent regulatory requirements
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Synthetic compounds
- 5.3 Polyether antibiotics or ionophores
Chapter 6 Market Estimates and Forecast, By Drug Action, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Coccidiostatic
- 6.3 Coccidiocidal
Chapter 7 Market Estimates and Forecast, By Animal Type, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Companion animals
- 7.2.1 Dogs
- 7.2.2 Cats
- 7.2.3 Other companion animals
- 7.3 Livestock animals
- 7.3.1 Cattle
- 7.3.2 Poultry
- 7.3.3 Other livestock animals
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Veterinary hospitals & pharmacies
- 8.3 Retail pharmacies
- 8.4 Other distribution channels
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Bayer AG
- 10.2 Boehringer Ingelheim International GmbH
- 10.3 Ceva
- 10.4 Cronus Pharma LLC
- 10.5 Elanco Animal Health Incorporated
- 10.6 Huvepharma EOOD
- 10.7 Impextraco NV
- 10.8 Merck & Co., Inc.
- 10.9 Phibro Animal Health Corporation
- 10.10 Vetoquinol SA
- 10.11 Virbac SA
- 10.12 Zoetis Inc.
